Sleep Apnea and Cardiovascular Disease: Telling the Tale from the Cardiologist's Point of View-Sleep Apnea and Cardiovascular Disease: Slides

Sleep Apnea and Cardiovascular Disease: Slides

Pdf Summary

The presentation reviews links between obstructive sleep apnea (OSA) and cardiovascular disease (CVD), emphasizing that coexistence does not necessarily prove causation. Repeated oxygen deprivation and reoxygenation, sleep disruption, autonomic changes, hypercapnia, and pressure shifts in the chest may promote sympathetic activation, inflammation, endothelial dysfunction, atherosclerosis, hypercoagulability, and cardiac structural changes. OSA is associated with hypertension, atrial fibrillation, heart failure, coronary disease, stroke, pulmonary hypertension, metabolic disease, and mortality.<br /><br />OSA treatment may lower blood pressure, but effects vary. In resistant hypertension, studies suggest CPAP reduces pressure by roughly 4–7 mmHg; oral appliances may reduce it by 2–3 mmHg. Greater BP responses are associated with uncontrolled or resistant hypertension, more severe oxygen desaturation and OSA, sleepiness, older age, and CPAP adherence.<br /><br />Sleepiness and oxygen burden may help identify higher-risk patients. Research cited links excessive daytime sleepiness with incident CVD, and suggests that myocardial infarction and sudden cardiac death occur more often during usual sleep hours among people with OSA.<br /><br />CPAP did not prevent cardiovascular events in the SAVE trial’s intention-to-treat analysis, although it improved quality of life and mood. Better outcomes, especially fewer cerebrovascular events, have been observed among adherent users; stopping CPAP has also been associated with increased risk. Potential explanations for mixed findings include limited adherence, enrollment of nonsleepy patients, and exclusion of people with severe hypoxemia.<br /><br />Weight-loss approaches are promising. Retrospective data associate metabolic surgery with lower MACE, mortality, and heart-failure risk in people with obesity and OSA. Tirzepatide trials showed substantial reductions in OSA severity and weight, alongside lower blood pressure. The presentation highlights treatment consideration for patients with marked sleepiness, hypoxemia, resistant hypertension, and obesity, using CPAP and appropriate weight-management options.

Keywords

obstructive sleep apnea

cardiovascular disease

CPAP therapy

resistant hypertension

atrial fibrillation

oxygen desaturation

sleepiness

weight loss

metabolic surgery

blood pressure reduction